Next Article in Journal
Plant/Bacterial Virus-Based Drug Discovery, Drug Delivery, and Therapeutics
Previous Article in Journal
Acid-Treated Water-Soluble Chitosan Suitable for Microneedle-Assisted Intracutaneous Drug Delivery
Open AccessMeeting Report

Nanomedicines for the Delivery of Biologics

1
The Academy of Pharmaceutical Sciences, 4 Heydon Road, Great Chishill, Royston SG8 8SR, UK
2
Advanced Drug Delivery, Pharmaceutical Sciences, IMED Biotech Unit, AstraZeneca, Granta Park, Cambridge CB21 6GH, UK
3
Reading School of Pharmacy, University of Reading, Whiteknights, Reading RG6 6AP, UK
4
Global Product Development, Pharmaceutical Technology and Development, Operations, AstraZeneca, Macclesfield SK10 2NA, UK
5
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff CF10 3NB, UK
6
Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK
7
Pharmaceutical and Pharmacological Sciences Department, University of Padova, F. Marzolo 5, 35131 Padova, Italy
8
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK
9
Department of Oncology, Old Road Campus Research Building, Oxford OX3 7DQ, UK
10
UCL School of Pharmacy, London WC1N 1AX, UK
*
Author to whom correspondence should be addressed.
Pharmaceutics 2019, 11(5), 210; https://doi.org/10.3390/pharmaceutics11050210
Received: 3 April 2019 / Accepted: 4 April 2019 / Published: 3 May 2019
A special symposium of the Academy of Pharmaceutical Sciences Nanomedicines Focus Group reviewed the current status of the use of nanomedicines for the delivery of biologics drugs. This meeting was particularly timely with the recent approval of the first siRNA-containing product Onpattro™ (patisiran), which is formulated as a lipid nanoparticle for intravenous infusion, and the increasing interest in the use of nanomedicines for the oral delivery of biologics. The challenges in delivering such molecules were discussed with specific emphasis on the delivery both across and into cells. The latest developments in Molecular Envelope Technology® (Nanomerics Ltd, London, UK), liposomal drug delivery (both from an academic and industrial perspective), opportunities offered by the endocytic pathway, delivery using genetically engineered viral vectors (PsiOxus Technologies Ltd, Abingdon, UK), Transint™ technology (Applied Molecular Transport Inc., South San Francisco, CA, USA), which has the potential to deliver a wide range of macromolecules, and AstraZeneca’s initiatives in mRNA delivery were covered with a focus on their uses in difficult to treat diseases, including cancers. Preclinical data were presented for each of the technologies and where sufficiently advanced, plans for clinical studies as well as early clinical data. The meeting covered the work in progress in this exciting area and highlighted some key technologies to look out for in the future. View Full-Text
Keywords: nanomedicines; drug delivery; siRNA; mRNA; DNA; proteins; lipid nanoparticles; liposomes; viral vectors; endocytosis nanomedicines; drug delivery; siRNA; mRNA; DNA; proteins; lipid nanoparticles; liposomes; viral vectors; endocytosis
Show Figures

Figure 1

MDPI and ACS Style

Wahlich, J.; Desai, A.; Greco, F.; Hill, K.; Jones, A.T.; Mrsny, R.J.; Pasut, G.; Perrie, Y.; Seib, F.P.; Seymour, L.W.; Uchegbu, I.F. Nanomedicines for the Delivery of Biologics. Pharmaceutics 2019, 11, 210.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop